<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   NSAIDs: Electrolyte complications
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       NSAIDs: Electrolyte complications
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        NSAIDs: Electrolyte complications
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Sterns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Emmett, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Mar 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nonsteroidal antiinflammatory drugs (NSAIDs) are the most commonly prescribed analgesics worldwide. These agents reduce pain, inflammation, and fever by inhibiting cyclooxygenase (COX), which results in decreased synthesis of prostaglandins. COX has two isoforms; inhibition of COX-1 is responsible for the gastrointestinal side effects of NSAIDs, while their desired antiinflammatory effects are due to inhibition of COX-2 [
         <a href="#rid1">
          1
         </a>
         ]. The COX-2 isoform is constitutively present in the kidney, and, therefore, both nonselective NSAIDs and more selective COX-2 inhibitors reduce renal prostaglandins. (See
         <a class="medical medical_review" href="/z/d/html/7989.html" rel="external">
          "NSAIDs (including aspirin): Pharmacology and mechanism of action"
         </a>
         .)
        </p>
        <p>
         Renal vasodilatory prostaglandins promote the secretion of renin, impair sodium reabsorption in the loop of Henle and cortical collecting tubule, and partially antagonize the ability of antidiuretic hormone (ADH) to increase water reabsorption in the collecting tubules [
         <a href="#rid2">
          2-5
         </a>
         ]. Locally generated prostaglandins also may mediate part of the natriuretic effect of dopamine and of natriuretic peptides [
         <a href="#rid6">
          6,7
         </a>
         ].
        </p>
        <p>
         These actions are not of major importance in normal subjects in whom basal renal prostaglandin production is relatively low. However, they may become clinically significant when prostaglandin synthesis is stimulated by underlying kidney disease or by the vasoconstrictors angiotensin II or norepinephrine. Secretion of these vasoconstrictors is increased in states of effective volume depletion: true volume depletion due to gastrointestinal or renal losses (as with diuretic therapy) or reduced tissue perfusion due to heart failure or cirrhosis.
        </p>
        <p>
         In the setting of effective volume depletion, NSAIDs, which inhibit prostaglandin synthesis, can produce a variety of complications related to kidney dysfunction, each of which is reversible with discontinuation of therapy [
         <a href="#rid2">
          2,3
         </a>
         ]. These include hyperkalemia, hyponatremia, and edema. These complications are mediated in part by reductions in the secretion of renin and aldosterone and by increased activity of ADH [
         <a href="#rid2">
          2,3,8
         </a>
         ].
        </p>
        <p>
         In addition, vasoconstriction due to decreased synthesis of vasodilator prostaglandins can impair kidney function and exacerbate underlying hypertension and heart failure. These issues are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7230.html" rel="external">
          "NSAIDs: Acute kidney injury"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2385.html" rel="external">
          "NSAIDs and acetaminophen: Effects on blood pressure and hypertension"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7968.html" rel="external">
          "NSAIDs: Adverse cardiovascular effects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ELECTROLYTE COMPLICATIONS
         </span>
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Hyperkalemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         NSAIDs have two effects that can promote the development of hyperkalemia: They lower renin secretion by the kidney, which is normally mediated, in part, by locally produced prostaglandins [
         <a href="#rid2">
          2,3,9
         </a>
         ], and they impair angiotensin II-induced aldosterone release [
         <a href="#rid9">
          9
         </a>
         ]. The ensuing fall in aldosterone secretion will reduce urinary potassium excretion, which will tend to raise the plasma potassium concentration.
        </p>
        <p>
         The magnitude of the effect of NSAIDs on the plasma potassium concentration was illustrated in a study of 50 hospitalized patients in whom
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         therapy was initiated [
         <a href="#rid10">
          10
         </a>
         ]. The plasma potassium rose by less than 0.5 mEq/L in 40 percent, 0.5 to 0.9 mEq/L in 34 percent, and by 1 mEq/L or more in 26 percent; these changes began within the first few days of therapy. One would expect smaller elevations in plasma potassium in healthy individuals. On the other hand, the hyperkalemic effect may be more pronounced in two settings: if there is an NSAID-induced reduction in glomerular filtration rate, which can lead to reduced sodium and water delivery to the potassium secretory site in the collecting tubules, or if there is concurrent use of other drugs that raise the plasma potassium such as angiotensin inhibitors and potassium-sparing diuretics [
         <a href="#rid3">
          3
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7230.html" rel="external">
          "NSAIDs: Acute kidney injury", section on 'Mechanism of acute kidney injury'
         </a>
         .)
        </p>
        <p>
         In the absence of other risk factors, NSAIDs are unlikely to produce moderate to severe hyperkalemia. In an observational study of 1,267,025 new NSAID users, for example, NSAID use alone was not associated with the development of hyperkalemia (defined as a serum potassium ≥6 mEq/L) [
         <a href="#rid11">
          11
         </a>
         ]. However, the risk for this degree of hyperkalemia was increased when NSAIDs were combined with an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), or with radiocontrast media exposure. In another large study that examined new use of NSAIDs among older adults, moderate hyperkalemia (≥5.5 mEq/L) was twice as common in the first month of NSAID use (0.40 versus 0.27 percent among non-users), although rates of more severe hyperkalemia (≥6.0 or ≥6.5 mEq/L) were similar [
         <a href="#rid12">
          12
         </a>
         ]. Baseline serum potassium, estimated glomerular filtration rate (eGFR), ACE inhibitor or ARB use, diuretic use, and NSAID dose did not significantly modify the association between NSAID use and hyperkalemia.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Hyponatremia
         </span>
         <span class="headingEndMark">
          —
         </span>
         NSAIDs diminish the normal inhibitory effect of prostaglandins on the activity of antidiuretic hormone (ADH) and can therefore reduce free water excretion [
         <a href="#rid4">
          4,13
         </a>
         ]. In conditions associated with high and relatively nonsuppressible levels of ADH, such as the syndrome of inappropriate ADH secretion or effective volume depletion, as in patients with severe heart failure, NSAID-induced water retention can induce or worsen hyponatremia [
         <a href="#rid2">
          2,14
         </a>
         ]. NSAIDs may also increase the susceptibility of older adults to thiazide diuretic-induced hyponatremia [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2321.html" rel="external">
          "Hyponatremia in patients with heart failure"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2288.html" rel="external">
          "Diuretic-induced hyponatremia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Edema
         </span>
         <span class="headingEndMark">
          —
         </span>
         Removal of the inhibitory effect of prostaglandins on sodium reabsorption with both nonselective and cyclooxygenase (COX)-selective NSAIDs can lead to sodium retention. With prolonged therapy, healthy individuals may have a weight gain of as much as 0.5 to 1 kg, while the degree of sodium and water retention may be more prominent in patients with underlying heart failure or cirrhosis [
         <a href="#rid3">
          3,16
         </a>
         ]. The increase in sodium reabsorption contributes to the relative resistance to diuretics associated with NSAID therapy [
         <a href="#rid3">
          3,17
         </a>
         ]. NSAIDs may also exacerbate heart failure, an effect that is probably due more to increased afterload resulting from NSAID-induced systemic vasoconstriction than to sodium retention. (See
         <a class="medical medical_review" href="/z/d/html/7968.html" rel="external">
          "NSAIDs: Adverse cardiovascular effects"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1151981013">
         <span class="h2">
          Hypokalemia and renal tubular acidosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several patients with ibuprofen-induced renal tubular acidosis (RTA) associated with profound hypokalemia (serum potassium as low as 1 mmol/L) have been reported [
         <a href="#rid18">
          18-24
         </a>
         ]. The first cases were identified in Australia, where ibuprofen-codeine combination products are available over the counter, and most, but not all, were taking excessive doses of
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         [
         <a href="#rid18">
          18,19
         </a>
         ]. However, subsequent reports have revealed that this NSAID complication is not limited to concurrent
         <a class="drug drug_general" data-topicid="9291" href="/z/d/drug information/9291.html" rel="external">
          codeine
         </a>
         use or to toxic doses of ibuprofen [
         <a href="#rid20">
          20-24
         </a>
         ].
        </p>
        <p>
         As of July 2022, there were 41 published reports describing 50 cases (26 males and 24 females; 36 adults and 14 children) with often profound hypokalemia, acidosis, or both after ingestion of
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         ; 88 percent of the patients were taking an excessive dose (more than 40 mg/kg body weight daily), but 12 percent were taking normal doses [
         <a href="#rid24">
          24
         </a>
         ]. Approximately half of these cases occurred after a single large dose (96 to &gt;1000 mg/kg) and approximately half after nontoxic doses taken for a longer period (from two weeks to over a year).
        </p>
        <p>
         Most acute
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         overdoses produced an elevated anion gap, often with documented lactic acidosis and normal or elevated serum potassium. By contrast, the more chronic cases presented with hypokalemia, a hyperchloremic metabolic acidosis, a urine pH &gt;5.5, and a low urine anion gap consistent with a diagnosis of RTA. Urinary potassium wasting was documented in all cases and was not explained by diuretic use or magnesium deficiency. Renal glycosuria was not observed. In most patients, discontinuation of ibuprofen resulted in complete biochemical resolution within days. The mechanism by which ibuprofen induces RTA is unknown.
        </p>
        <p>
         Hypokalemia has been reported in one patient taking
         <a class="drug drug_general" data-topicid="9682" href="/z/d/drug information/9682.html" rel="external">
          naproxen
         </a>
         , which, like
         <a class="drug drug_general" data-topicid="8547" href="/z/d/drug information/8547.html" rel="external">
          ibuprofen
         </a>
         , is a propionic acid derivative, but it has not been associated with other classes of NSAIDs.
        </p>
        <p class="headingAnchor" id="H22536456">
         <span class="h1">
          CHOICE OF NSAID
         </span>
         <span class="headingEndMark">
          —
         </span>
         The above complications can generally be induced by any of the NSAIDs, although
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         may be the most potent. In comparison, renal prostaglandin synthesis may be relatively spared following therapy with
         <a class="drug drug_general" data-topicid="9967" href="/z/d/drug information/9967.html" rel="external">
          sulindac
         </a>
         or low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         [
         <a href="#rid3">
          3,25
         </a>
         ]. With aspirin, for example, the inhibition of glomerular cyclooxygenase (COX) may only be partial and transient, in contrast to the irreversible acetylation in platelets [
         <a href="#rid25">
          25
         </a>
         ]. The possible mechanisms by which sulindac might, in some patients, spare renal prostaglandin synthesis are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/7230.html" rel="external">
          "NSAIDs: Acute kidney injury", section on 'Mechanism of acute kidney injury'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H612385">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonsteroidal antiinflammatory drugs (NSAIDs) inhibit prostaglandin synthesis. In the setting of effective volume depletion, this inhibition can cause hyperkalemia, hyponatremia, and edema. (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NSAIDs cause hyperkalemia by decreasing renin secretion and impairing angiotensin II-induced aldosterone release. The ensuing fall in aldosterone secretion reduces urinary potassium excretion, which raises the plasma potassium concentration. (See
         <a class="local">
          'Hyperkalemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NSAIDs diminish the inhibitory effect of prostaglandins on the activity of antidiuretic hormone (ADH); the ensuing increase in ADH activity can reduce free water excretion, which can lead to water retention and induction or exacerbation of hyponatremia in conditions associated with high and nonsuppressible levels of ADH, such as the syndrome of inappropriate ADH secretion or effective volume depletion, as in patients with severe heart failure or cirrhosis. NSAIDs may also increase the susceptibility of older adult subjects to thiazide diuretic-induced hyponatremia. (See
         <a class="local">
          'Hyponatremia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         NSAIDs can cause sodium retention that is typically mild in healthy individuals but can lead to exacerbation of edema and contribute to diuretic resistance in patients with underlying heart failure or cirrhosis. (See
         <a class="local">
          'Edema'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Rarely, NSAIDs may produce hypokalemia and metabolic acidosis. (See
         <a class="local">
          'Hypokalemia and renal tubular acidosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The above complications can generally be induced by any of the NSAIDs, although
         <a class="drug drug_general" data-topicid="8559" href="/z/d/drug information/8559.html" rel="external">
          indomethacin
         </a>
         may be the most potent and
         <a class="drug drug_general" data-topicid="9967" href="/z/d/drug information/9967.html" rel="external">
          sulindac
         </a>
         or low-dose
         <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">
          aspirin
         </a>
         the least potent. (See
         <a class="local">
          'Choice of NSAID'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Green T, Gonzalez AA, Mitchell KD, Navar LG. The complex interplay between cyclooxygenase-2 and angiotensin II in regulating kidney function. Curr Opin Nephrol Hypertens 2012; 21:7.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oates JA, FitzGerald GA, Branch RA, et al. Clinical implications of prostaglandin and thromboxane A2 formation (2). N Engl J Med 1988; 319:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schlondorff D. Renal complications of nonsteroidal anti-inflammatory drugs. Kidney Int 1993; 44:643.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kramer HJ, Glänzer K, Düsing R. Role of prostaglandins in the regulation of renal water excretion. Kidney Int 1981; 19:851.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hébert RL, Jacobson HR, Breyer MD. Prostaglandin E2 inhibits sodium transport in rabbit cortical collecting duct by increasing intracellular calcium. J Clin Invest 1991; 87:1992.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Satoh T, Cohen HT, Katz AI. Intracellular signaling in the regulation of renal Na-K-ATPase. I. Role of cyclic AMP and phospholipase A2. J Clin Invest 1992; 89:1496.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gunning ME, Brady HR, Otuechere G, et al. Atrial natriuretic peptide(31-67) inhibits Na+ transport in rabbit inner medullary collecting duct cells. Role of prostaglandin E2. J Clin Invest 1992; 89:1411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stichtenoth DO, Marhauer V, Tsikas D, et al. Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers. Kidney Int 2005; 68:2197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell WB, Gomez-Sanchez CE, Adams BV, et al. Attenuation of angiotensin II- and III-induced aldosterone release by prostaglandin synthesis inhibitors. J Clin Invest 1979; 64:1552.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimran A, Kramer M, Plaskin M, Hershko C. Incidence of hyperkalaemia induced by indomethacin in a hospital population. Br Med J (Clin Res Ed) 1985; 291:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lafrance JP, Miller DR. Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study. Am J Kidney Dis 2012; 60:82.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nash DM, Markle-Reid M, Brimble KS, et al. Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study. Nephrol Dial Transplant 2019; 34:1145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walker RM, Brown RS, Stoff JS. Role of renal prostaglandins during antidiuresis and water diuresis in man. Kidney Int 1982; 21:365.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dzau VJ, Packer M, Lilly LS, et al. Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia. N Engl J Med 1984; 310:347.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clark BA, Shannon RP, Rosa RM, Epstein FH. Increased susceptibility to thiazide-induced hyponatremia in the elderly. J Am Soc Nephrol 1994; 5:1106.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984; 310:563.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brater DC. Analysis of the effect of indomethacin on the response to furosemide in man: effect of dose of furosemide. J Pharmacol Exp Ther 1979; 210:386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ng JL, Morgan DJ, Loh NK, et al. Life-threatening hypokalaemia associated with ibuprofen-induced renal tubular acidosis. Med J Aust 2011; 194:313.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Page CB, Wilson PA, Foy A, et al. Life-threatening hypokalaemia associated with ibuprofen-induced renal tubular acidosis. Med J Aust 2011; 194:614.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watanabe T. Ibuprofen-Induced Renal Tubular Acidosis. Kidney Int Rep 2019; 4:360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thammineni N, Kathi PR, Sharma A, Jawed A. Ibuprofen Overuse Leading to Life-threatening Hypokalemia Associated with Renal Tubular Acidosis in Two Patients. Cureus 2019; 11:e6404.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li R, Hasan N, Armstrong L, Cockings J. Impaired consciousness, hypokalaemia and renal tubular acidosis in sustained Nurofen Plus abuse. BMJ Case Rep 2019; 12.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chhabria M, Portales-Castillo I, Chowdhury M, et al. A Case of Severe Hypokalemia. Am J Kidney Dis 2020; 76:A9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Man AM, Piffer A, Simonetti GD, et al. Ibuprofen-Associated Hypokalemia and Metabolic Acidosis: Systematic Literature Review. Ann Pharmacother 2022; :10600280221075362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69:1366.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2299 Version 15.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22080858" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : The complex interplay between cyclooxygenase-2 and angiotensin II in regulating kidney function.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3045551" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Clinical implications of prostaglandin and thromboxane A2 formation (2).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8231040" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Renal complications of nonsteroidal anti-inflammatory drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7021956" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Role of prostaglandins in the regulation of renal water excretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1645747" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Prostaglandin E2 inhibits sodium transport in rabbit cortical collecting duct by increasing intracellular calcium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1349027" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Intracellular signaling in the regulation of renal Na-K-ATPase. I. Role of cyclic AMP and phospholipase A2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1533229" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Atrial natriuretic peptide(31-67) inhibits Na+ transport in rabbit inner medullary collecting duct cells. Role of prostaglandin E2.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16221219" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Effects of specific COX-2-inhibition on renin release and renal and systemic prostanoid synthesis in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/500824" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Attenuation of angiotensin II- and III-induced aldosterone release by prostaglandin synthesis inhibitors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3926071" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Incidence of hyperkalaemia induced by indomethacin in a hospital population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22503390" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Dispensed selective and nonselective nonsteroidal anti-inflammatory drugs and the risk of moderate to severe hyperkalemia: a nested case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31264694" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Nonsteroidal anti-inflammatory drug use and risk of acute kidney injury and hyperkalemia in older adults: a population-based study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6951096" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Role of renal prostaglandins during antidiuresis and water diuresis in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6361570" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Prostaglandins in severe congestive heart failure. Relation to activation of the renin--angiotensin system and hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7849250" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Increased susceptibility to thiazide-induced hyponatremia in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6363936" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Renal syndromes associated with nonsteroidal antiinflammatory drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/480189" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Analysis of the effect of indomethacin on the response to furosemide in man: effect of dose of furosemide.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21426288" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Life-threatening hypokalaemia associated with ibuprofen-induced renal tubular acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21644884" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Life-threatening hypokalaemia associated with ibuprofen-induced renal tubular acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30775637" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Ibuprofen-Induced Renal Tubular Acidosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31970034" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Ibuprofen Overuse Leading to Life-threatening Hypokalemia Associated with Renal Tubular Acidosis in Two Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31780600" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Impaired consciousness, hypokalaemia and renal tubular acidosis in sustained Nurofen Plus abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32571502" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : A Case of Severe Hypokalemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35135381" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ibuprofen-Associated Hypokalemia and Metabolic Acidosis: Systematic Literature Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7045161" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
